A comparison of triple therapy drug regimen duration for the eradication of Helicobacter pylori in adults attending a Nairobi gastroenterology clinic
- Conditions
- Helicobacter pylori gastritis
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 114
Presence of at least two of the following symptoms; upper abdominal pain or discomfort, bloating, nausea, vomiting or early satiety.
Persistent or recurrent symptoms occurring at least three times per week during six or more months in the year(s) preceding the study.
Age 18 years and above.
Written informed consent.
H. pylori positive on rapid urease test.
Previous treatment for H. pylori less than 4 weeks prior to endoscopy.
Allergy to penicillins or macrolides.
Significant liver or kidney disease.
Severe cardiac or pulmonary disease.
Suspected or confirmed malignancy.
Concurrent reflux oesophagitis.
Active upper gastrointestinal bleeding.
History of gastric surgery except uncomplicated appendectomy, cholecystectomy or hernia repair.
Pregnancy or breast-feeding.
Patients using antibiotics in the month before inclusion, bismuth-containing compounds during the 3 months before inclusion, or Proton pump inhibitors, H2 receptor antagonists, misoprostol or sucralfate in the 2 weeks before the pre-entry endoscopy.
Patients receiving regular treatment with Non-steroidal analgesics more than or equal to 5 days a week, for at least 2 weeks during the month before the start of the study.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Eradication of H. pylori infection
- Secondary Outcome Measures
Name Time Method Prevalence of H. pylori infection in patients undergoing endoscopy;Efficacy of H. pylori drug regime